Rossella Loria
Overview
Explore the profile of Rossella Loria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blandino G, Dinami R, Marcia M, Anastasiadou E, Ryan B, Palcau A, et al.
J Exp Clin Cancer Res
. 2023 Jul;
42(1):189.
PMID: 37507791
The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) on 27-28 March at the IRCCS Regina Elena National Cancer Institute. This meeting entitled "The New World of...
2.
Loria R, Vici P, Di Lisa F, Soddu S, Maugeri-Sacca M, Bon G
Front Oncol
. 2022 Nov;
12:1063651.
PMID: 36387137
[This corrects the article DOI: 10.3389/fonc.2022.877380.].
3.
Loria R, Vici P, Di Lisa F, Soddu S, Maugeri-Sacca M, Bon G
Front Oncol
. 2022 Jul;
12:877380.
PMID: 35814399
Over the past two decades, cancer treatment has benefited from having a significant increase in the number of targeted drugs approved by the United States Food and Drug Administration. With...
4.
Loria R, Laquintana V, Scalera S, Fraioli R, Caprara V, Falcone I, et al.
J Exp Clin Cancer Res
. 2022 Apr;
41(1):148.
PMID: 35440004
Background: Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed....
5.
Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchio C, et al.
J Exp Clin Cancer Res
. 2020 Dec;
39(1):279.
PMID: 33302999
Background: HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the...
6.
Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, et al.
Front Oncol
. 2020 Jul;
10:944.
PMID: 32656080
[This corrects the article DOI: 10.3389/fonc.2020.00489.].
7.
Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, et al.
Front Oncol
. 2020 May;
10:489.
PMID: 32351889
This work describes the set-up of a shared platform among the laboratories of the Alleanza Contro il Cancro (ACC) Italian Research Network for the identification of fusion transcripts in sarcomas...
8.
Bacci L, Aiello A, Ripoli C, Loria R, Pugliese D, Pierconti F, et al.
Int J Mol Sci
. 2019 Aug;
20(16).
PMID: 31426484
Estrogen and hypoxia promote an aggressive phenotype in prostate cancer (PCa), driving transcription of progression-associated genes. Here, we molecularly dissect the contribution of long non-coding RNA H19 to PCa metastatic...
9.
Vizza E, Mancini E, Laquintana V, Loria R, Carosi M, Baiocco E, et al.
Surg Oncol
. 2019 Mar;
28:151-157.
PMID: 30851892
Background: The aim of this study was to evaluate the prognostic role of positive peritoneal cytology (PPC) in a cohort of patients with endometrial cancer (EC). The secondary objective was...
10.
Loria R, Giliberti C, Bedini A, Palomba R, Caracciolo G, Ceci P, et al.
J Exp Clin Cancer Res
. 2019 Jan;
38(1):1.
PMID: 30606223
Background: The possibility to combine Low Intensity UltraSound (LIUS) and Nanoparticles (NP) could represent a promising strategy for drugs delivery in tumors difficult to treat overcoming resistance to therapies. On...